Danish medico giant Novo Nordisk has inaugurated a major expansion of its production facilities in Montes Claros, Brazil. About USD 200 m has been invested in the new insulin plant, making it the largest single investment in the history of the pharmaceutical industry in Brazil. The Brazilian Vice President José Alencar Gomes da Silva and the Danish Prime Minister Anders Fogh Rasmussen attended the inauguration.
Lars Rebien Sørensen, president and CEO of Novo Nordisk, commented: “The new Montes Claros facility is a cornerstone in the company’s global operations and reflects our commitment to the Brazilian market.”
The new plant will formulate and fill insulin cartridges which are used in the insulin pen systems marketed by Novo Nordisk. Around 95% of the Montes Claros plant's output will be exported to other parts of the world including Europe, Australia, New Zealand and Canada.
Novo Nordisk recently approved an additional USD 50 m investment for the construction of a pre-filled insulin pen manufacturing facility in Montes Claros. The new facility is expected to be operational by 2009. The news was reported by financial daily newspaper Børsen.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company also has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London.